drugset / Trial / NCT03716856
Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma
Phase 1
Unknown
11 enrolled
First Affiliated Hospital of Zhejiang University
CARsgen Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR-BCMA T cells in patients with BCMA-positive refractory or relapsed multiple myeloma.
Timeline
- Start
- 2018-03-23
- Primary completion
- 2020-06-23
- Completion
- 2023-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-BCMA T cells | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |